Maria Dall'era, MD

Professor

Maria Dall’Era is the Jean S. Engleman Distinguished Professor of Medicine and Chief of the Division of Rheumatology at the University of California, San Francisco (UCSF). She is the Director of the UCSF Rheumatology Clinical Research Center and Co-director of the UCSF Lupus Clinic.
Dr. Dall'Era received her undergraduate degree in Immunology from the University of California, Berkeley and completed her medical degree, residency in internal medicine, chief residency, and rheumatology fellowship at the University of California, San Francisco. She is a clinical researcher and practicing rheumatologist, specializing in systemic lupus erythematosus (SLE).

Dr. Dall'Era's scholarly activities focus on the development of novel therapies and the epidemiology and outcomes of people living with SLE and lupus nephritis. She is the PI of a CDC-funded population- based longitudinal lupus cohort in the San Francisco Bay Area called the California Lupus Epidemiology Study and the PI on clinical trials focused on SLE and lupus nephritis (LN).

She holds several international and national leadership positions including serving as Co-Chair of the Lupus Therapeutics Board of Directors, Co-Chair of the LRA's Lupus Industry Council, and member of the Lupus Accelerating Breakthroughs Consortium Research Committee. She is also a steering committee member of the Lupus Academy and Lupus Forum.
She serves as a member of the core leadership team overseeing the development of the American College of Rheumatology's Guidelines for the Treatment of SLE and LN.

She has authored numerous publications in the areas of SLE and lupus nephritis. She is a co-author of the Treatment of Lupus Nephritis chapters in Up-To-Date.

She has received several honors and awards for her work including the UCSF Exceptional Physician Award, the Ephraim Engleman Award for Arthritis Research, the Edmund L. Dubois Memorial Lectureship Award from the American College of Rheumatology, and the Evelyn V. Hess award from the Lupus Foundation of America.

Education
Fellow, 2004 - Rheumatology, University of California, San Francisco
M.D., 1997 - School of Medicine, University of California, San Francisco
BA, 1993 - Immunology, University of California, Berkeley
Residency, - School of Medicine, University of California, San Francisco
Honors and Awards
  • Evelyn V. Hess Award, Lupus Foundation of America, 2023
  • Edmund L. Dubois Memorial Lectureship Award, American College of Rheumatology, 2018
  • Purple Ribbon Award, Lupus Foundation of America, 2014
  • Exceptional Physician Award, UCSF, 2010
  • Ira M. Goldstein Award for Outstanding Teaching in Rheumatology, UCSF, 2007
  • Ephraim Engleman Award for Excellence in Arthritis Research, UCSF, 2006
Websites
Publications

  1. Furie RA, Dall'Era M, Vital EM, Garg JP, Irazoque Palazuelos F, Zuta Santillán AE, Ravelo-Hernández J, Santiago MB, Zazueta Montiel B, Botha S, Leszczynski P, de Souza VA, Sicsik SA, Bellatin L, Naidoo A, Amoura Z, D'Agostino MA, Kumar S, Workeneh B, Rae J, Mao HA, Erblang F, Meier O, Maller JC, Askanase AD, ALLEGORY Trial Investigators. Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus. The New England journal of medicine 2026. PMID: 41789864


  2. Benson KRK, Becerril A, Park J, Plantinga L, Yazdany J, Dall'Era M, Katz PP. The Impact of Everyday Discrimination on Systemic Lupus Erythematous Disease Activity and Mental Health Outcomes. The Journal of rheumatology 2025. PMID: 41397863


  3. Plantinga LC, Fitzpatrick J, Dey M, Dall'Era M, Dunlop-Thomas C, Hoge C, Lim SS, Katz PP, Yazdany J. Perceived and Objective Physical Function in Two U.S., Population-Based Cohorts of Adults with Systemic Lupus Erythematosus. The Journal of rheumatology 2026. PMID: 41539724


  4. Caricchio R, Bell S, Bernatsky S, Dall'Era M, Goddard D, Kalunian K, Kim AHJ, Koumpouras F, Rubio J, Saxena A, Sheikh S, Lupus Clinical Investigators Network. A Guide for Initiating and Managing Chimeric Antigen Receptor T Cell Therapy Clinical Trials in Autoimmune Rheumatic Diseases. ACR Open Rheumatology 2025. PMID: 41315006


  5. Kawtharany H, Jorge A, Azzam M, Bartels CM, Cunha JS, DeQuattro K, Fava A, Figueroa-Parra G, Garg S, Greco J, Cuéllar-Gutiérrez MC, Iyer P, Johannemann AS, Kasturi S, Khawandi J, Kirou KA, Legge A, Liang KV, Lockwood MM, Sanchez-Rodriguez A, Turgunbaev M, Williams JN, Sammaritano LR, Askanase A, Bermas BL, Dall'Era M, Duarte-García A, Hiraki LT, Rovin B, Son MBF, Turner AS, Mustafa RA. Renal Replacement Therapy in Lupus Nephritis-Related End-Stage Kidney Disease: A Systematic Review and Meta-Analysis. ACR Open Rheumatology 2025. PMID: 41294263


  6. Sammaritano LR, Askanase A, Bermas BL, Dall'Era M, Duarte-García A, Hiraki LT, Son MBF, Werth VP, Aranow C, Barnado A, Broder A, Brunner HI, Chong BF, Chowdhary VR, Hersh AO, Izmirly PM, Jules M, Kalunian K, Kamen D, Rubinstein TB, Smith BJ, Smith NM, Thomas A, Timlin H, Wallace DJ, Azzam M, Bartels CM, Cunha JS, DeQuattro K, Fava A, Figueroa-Parra G, Garg S, Gomes LLA, Cuéllar-Gutiérrez MC, Iyer P, Johannemann AS, Jorge A, Kasturi S, Kawtharany H, Khawandi J, Legge A, Liang KP, Lockwood MM, Sanchez-Rodriguez A, Turgunbaev M, Williams JN, Turner AS, Mustafa RA. 2025 American College of Rheumatology (ACR) Guideline for the Treatment of Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) 2025. PMID: 41187097


  7. Garg S, Hartel I, Sammaritano LR, Askanase A, Bermas BL, Dall'Era M, Duarte-García A, Werth VP, Rovin B, Mustafa RA, Turner AS, Williams B, Ung BL, Bhavsar H, Gore-Massy MC, Pulido N, Guerrero N, Smith NM, Machua W, Hiraki LT, Son MB. A Qualitative Analysis of Patient Perspectives and Preferences in Lupus Management to Guide Lupus Guidelines Development. Arthritis care & research 2025. PMID: 41182325


  8. Gilman SD, Johnson S, Carpenter K, French M, Castle P, Lim SS, Dunlop-Thomas C, Drenkard C, Dall'Era M, Somers EC, Zick S, Miller M, Wallace DJ, Werth VP, Crimmings M. Programme evaluation of Strategies to Embrace Living with Lupus Fearlessly (SELF): an evidence-based digital programme to build and improve lupus self-management skills. Lupus science & medicine 2025. PMID: 41062164


  9. Fava A, Wagner CA, Guthridge CJ, Macwana S, DeJager W, Munroe ME, Izmirly P, Belmont HM, Diamond B, Davidson A, Utz PJ, Weisman MH, Carlucci PM, Dall'Era M, Kalunian K, Putterman C, Anolik J, Barnas JL, Wofsy D, Kamen D, Furie RA, Rao DA, Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus Network, Petri M, Guthridge JM, Buyon J, James JA. Serum Soluble Mediator Signatures of Lupus Nephritis: Histologic Features and Response to Treatment. Arthritis care & research 2025. PMID: 41048053


  10. Sammaritano LR, Askanase A, Bermas BL, Dall'Era M, Duarte-Garcia A, Hiraki LT, Rovin BH, Son MBF, Turner AS, Mustafa RA. Reply. Arthritis & rheumatology (Hoboken, N.J.) 2025. PMID: 40726197


  11. van Dooren HJ, van Schaik M, Dorjée AL, Arends EJ, Mackay M, Laura C, Fox DA, Wofsy D, Smilek D, Aranow C, Dall'Era M, Huizinga TWJ, van Kooten C, Toes REM, Diamond B, Teng YKO, Suurmond J. Differences in dynamics of specific anti-nuclear antibodies and their susceptibility to B cell targeting treatment in Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) 2025. PMID: 40356198


  12. Narendra R, Van Phan H, Patterson SL, Almonte-Loya A, Lydon EC, Lanata C, Love C, Park J, Shimoda M, Barcellos L, Mekonen H, Detweiler A, Deosthale P, Neff N, Criswell LA, Maliskova L, Eckalbar W, Fragiadakis GK, Yazdany J, Dall'Era M, Katz P, Ye CJ, Sirota M, Langelier CR. Epigenetic attenuation of interferon signaling is associated with aging-related improvements in systemic lupus erythematosus. Science translational medicine 2025. PMID: 40561001


  13. Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, Howard K, Hancock B, Fava A, Sasaki T, Ghosh T, Inamo J, Beuschel R, Cao Y, Preisinger K, Gutierrez-Arcelus M, Eisenhaure TM, Guthridge J, Hoover PJ, Dall'Era M, Wofsy D, Kamen DL, Kalunian KC, Furie R, Belmont M, Izmirly P, Clancy R, Hildeman D, Woodle ES, Apruzzese W, McMahon MA, Grossman J, Barnas JL, Payan-Schober F, Ishimori M, Weisman M, Kretzler M, Berthier CC, Hodgin JB, Demeke DS, Putterman C, Accelerating Medicines Partnership Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP RA/SLE, Brenner MB, Anolik JH, Raychaudhuri S, Hacohen N, James JA, Davidson A, Petri MA, Buyon JP, Diamond B, Zhang F, Lederer JA, Rao DA. Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. The Journal of clinical investigation 2025. PMID: 40536813


  14. Askanase A, Fanouriakis A, Agustin L, Dall'Era M, Mosca M, Tanaka Y. The Lupus Check 5 Tool: A Practical Approach to Initiating Treatment Reviews in Systemic Lupus Erythematosus. Rheumatology and therapy 2025. PMID: 40445564


  15. Askanase AD, Vital EM, Meier O, Turchetta A, Mao HA, Maller J, Ross Terres JA, Dall'Era M. Evaluating the concordance between BICLA and SRI4 in patients with systemic lupus erythematosus from the placebo arms of the EXPLORER and ATHOS trials. Lupus science & medicine 2025. PMID: 40389370


  16. Sammaritano LR, Askanase A, Bermas BL, Dall'Era M, Duarte-García A, Hiraki LT, Rovin B, Son MBF, Alvarado A, Aranow C, Barnado A, Broder A, Brunner HI, Chowdhary V, Contreras G, Felix C, Ferucci ED, Gibson KL, Hersh AO, Izmirly PM, Kalunian K, Kamen D, Rollins B, Smith BJ, Thomas A, Timlin H, Wallace DJ, Ward M, Azzam M, Bartels CM, Cunha JS, DeQuattro K, Fava A, Figueroa-Parra G, Garg S, Greco J, Cuéllar-Gutiérrez MC, Iyer P, Johannemann AS, Jorge A, Kasturi S, Kawtharany H, Khawandi J, Kirou KA, Legge A, Liang KV, Lockwood MM, Sanchez-Rodriguez A, Turgunbaev M, Williams JN, Turner AS, Mustafa RA. 2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis care & research 2025. PMID: 40127995


  17. Connelly K, Koelmeyer R, Ayton D, May J, Gregory K, Eades LE, Barallon R, Kandane-Rathnayake R, Golder V, Anzum A, Mydin M, Akther M, Friedman A, Askanase AD, Aranow C, Vital E, Pons-Estel G, Brunner H, Kalunian K, Dantata K, Arnaud L, Burke L, Simon LS, Zuraw Q, Garces S, Werth VP, Sun YB, Tanaka Y, Lahoud Y, Cornet A, Sorrentino A, Rahman A, Stevens A, Barbey C, Dey ID, Karis E, Bonfá E, Noss E, Smith EMD, Stojan G, Andersen J, Merola JF, Ross Terres JA, Buie J, Maller J, Mosca M, Hojnik M, Dall'Era M, Furie RA, van Vollenhoven RF, Banerjee S, Morand E, TRM-SLE Taskforce Members, Delphi Participants. Domains for inclusion in a novel Treatment Response Measure for Systemic Lupus Erythematosus (TRM-SLE): results of a modified Delphi study. Lupus science & medicine 2025. PMID: 40328675


  18. Askanase AD, Furie R, Dall'Era M, Bomback AS, Schwarting A, Zhao MH, Bruce IN, Khamashta M, Rubin B, Carroll A, Levy RA, van Vollenhoven R, Urowitz MB. Disease-Modifying Therapies in Lupus Nephritis: A Narrative Review Evaluating Currently Used Pharmacologic Agents. Rheumatology and therapy 2025. PMID: 40186747


  19. Carlucci PM, Preisinger K, Deonaraine KK, Zaminski D, Dall'Era M, Gold HT, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Furie R, Diamond B, Davidson A, Wofsy D, Kamen D, James JA, Guthridge JM, Apruzzese W, Rao D, Weisman MH, Accelerating Medicines Partnership in RA/SLE Network, Izmirly PM, Buyon J, Petri M. Extrarenal symptoms associate with worse quality of life in patients enrolled in the AMP RA/SLE Lupus Nephritis Network. Rheumatology (Oxford, England) 2024. PMID: 38530774


  20. Narendra R, Phan HV, Patterson SL, Almonte Loya AL, Lanata C, Love C, Park J, Lydon EC, Shimoda MA, Barcellos L, Mekonen H, Detweiler A, Deosthale P, Neff N, Criswell LA, Maliskova L, Eckalbar W, Fragiadakis G, Yazdany J, Dall'Era M, Katz P, Ye CJ, Sirota M, Langelier CR. Epigenetic attenuation of interferon signaling drives aging-related improvements in systemic lupus. medRxiv : the preprint server for health sciences 2025. PMID: 39974140


  21. Katz P, Dall'Era M, Plantinga L, Barbour KE, Greenlund KJ, Yazdany J. Measuring Frailty in Systemic Lupus Erythematosus. Arthritis care & research 2024. PMID: 39648405


  22. Horton MK, Nititham J, Taylor KE, Katz P, Ye CJ, Yazdany J, Dall'Era M, Hurabielle C, Barcellos LF, Criswell LA, Lanata CM. Changes in DNA methylation are associated with systemic lupus erythematosus flare remission and clinical subtypes. Clinical epigenetics 2024. PMID: 39696438


  23. Patterson SL, Van Phan H, Ye CJ, Lanata C, González SC, Park J, Criswell LA, Barbour KE, Yazdany J, Dall'Era M, Sirota M, Katz P, Langelier CR. Physical inactivity exacerbates pathologic inflammatory signalling at the single cell level in patients with systemic lupus. EBioMedicine 2024. PMID: 39531917


  24. Dall'Era M, Kalunian K, Solomons N, Truman M, Hodge LS, Yap E, Askanase AD. Comparison of a voclosporin-based triple immunosuppressive therapy to high-dose glucocorticoid-based immunosuppressive therapy: a propensity analysis of the AURA-LV and AURORA 1 studies and ALMS. Lupus science & medicine 2024. PMID: 39521453


  25. Cutts Z, Patterson S, Maliskova L, Taylor KE, Ye CJ, Dall'Era M, Yazdany J, Criswell LA, Fragiadakis GK, Langelier C, Capra JA, Sirota M, Lanata CM. Cell-Specific Transposable Element and Gene Expression Analysis Across Systemic Lupus Erythematosus Phenotypes. ACR Open Rheumatology 2024. PMID: 39143499


  26. Figueroa-Parra G, Cuéllar-Gutiérrez MC, González-Treviño M, Sanchez-Rodriguez A, Flores-Gouyonnet J, Meade-Aguilar JA, Prokop LJ, Murad MH, Dall'Era M, Rovin BH, Houssiau F, Tamirou F, Fervenza FC, Crowson CS, Putman MS, Duarte-García A. Impact of Glucocorticoid Dose on Complete Response, Serious Infections, and Mortality During the Initial Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis of the Control Arms of Randomized Controlled Trials. Arthritis & rheumatology (Hoboken, N.J.) 2024. PMID: 38766897


  27. Askanase AD, Furie RA, Dall'Era M, Bomback AS, Schwarting A, Zhao MH, Bruce IN, Khamashta M, Rubin B, Carroll A, Daniels M, Levy RA, van Vollenhoven R, Urowitz MB. Disease-modifying therapies in systemic lupus erythematosus for extrarenal manifestations. Lupus science & medicine 2024. PMID: 38777595


  28. DeQuattro K, Trupin L, Patterson S, Rush S, Gordon C, Greenlund KJ, Barbour KE, Lanata C, Criswell LA, Dall'Era M, Yazdany J, Katz PP. Positive psychosocial factors may protect against perceived stress in people with systemic lupus erythematosus with and without trauma history. Lupus science & medicine 2024. PMID: 38754905


  29. Horisberger A, Griffith A, Keegan J, Arazi A, Pulford J, Murzin E, Howard K, Hancock B, Fava A, Sasaki T, Ghosh T, Inamo J, Beuschel R, Cao Y, Preisinger K, Gutierrez-Arcelus M, Eisenhaure TM, Guthridge J, Hoover PJ, Dall'Era M, Wofsy D, Kamen DL, Kalunian KC, Furie R, Belmont M, Izmirly P, Clancy R, Hildeman D, Woodle ES, Apruzzese W, McMahon MA, Grossman J, Barnas JL, Payan-Schober F, Ishimori M, Weisman M, Kretzler M, Berthier CC, Hodgin JB, Demeke DS, Putterman C, Accelerating Medicines Partnership: RA/SLE Network, Brenner MB, Anolik JH, Raychaudhuri S, Hacohen N, James JA, Davidson A, Petri MA, Buyon JP, Diamond B, Zhang F, Lederer JA, Rao DA. Blood immunophenotyping identifies distinct kidney histopathology and outcomes in patients with lupus nephritis. bioRxiv : the preprint server for biology 2024. PMID: 38293222


  30. Lanata CM, Taylor KE, Hurst-Hopf J, Nititham J, Blazer A, Trupin L, Katz P, Dall'Era M, Yazdany J, Chung SA, Abrahamsson D, Gerona R, Criswell LA. Screening of environmental chemicals to characterize exposures in participants with Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) 2023. PMID: 38129991


  31. Izmirly PM, Kim MY, Carlucci PM, Preisinger K, Cohen BZ, Deonaraine K, Zaminski D, Dall'Era M, Kalunian K, Fava A, Belmont HM, Wu M, Putterman C, Anolik J, Barnas JL, Diamond B, Davidson A, Wofsy D, Kamen D, James JA, Guthridge JM, Apruzzese W, Rao DA, Weisman MH, Accelerating Medicines Partnership in RA/SLE Network, Petri M, Buyon J, Furie R. Longitudinal patterns and predictors of response to standard-of-care therapy in lupus nephritis: data from the Accelerating Medicines Partnership Lupus Network. Arthritis research & therapy 2024. PMID: 38378664


  32. Yelnik CM, Xie X, Guerra MM, Costedoat-Chalumeau N, Khosroshahi A, Kamen DL, Schwartz N, Katz P, Minett M, Amoss RT, Fu A, Guettrot-Imbert G, Lazaro E, Le Guern V, Oates J, Dall'Era M, Yazdany J, Molto A, Kim MY, Salmon JE. Prevalence of clinically meaningful antiphospholipid antibodies in patients with systemic lupus erythematosus varies by race and ethnicity. Annals of the rheumatic diseases 2023. PMID: 37875285


  33. Solomon O, Lanata CM, Adams C, Nititham J, Taylor KE, Chung SA, Yazdany J, Dall'Era M, Pons-Estel BA, Tusie-Luna T, Tsao B, Morand E, Alarcón-Riquelme ME, Barcellos LF, Criswell LA. Local ancestry at the MHC region is not a major contributor to disease heterogeneity in a multi-ethnic lupus cohort. Arthritis & rheumatology (Hoboken, N.J.) 2023. PMID: 38073021


  34. Chakravarty EF, Utset T, Kamen DL, Contreras G, McCune WJ, Aranow C, Kalunian K, Massarotti E, Clowse MEB, Rovin BH, Lim SS, Majithia V, Dall'Era M, Looney RJ, Erkan D, Saxena A, Olsen NJ, Ko K, Guthridge JM, Goldmuntz E, Springer J, D'Aveta C, Keyes-Elstein L, Barry B, Pinckney A, McNamara J, James JA. Mycophenolate mofetil withdrawal in patients with systemic lupus erythematosus: a multicentre, open-label, randomised controlled trial. The Lancet. Rheumatology 2024. PMID: 38301682


  35. Fava A, Buyon J, Magder L, Hodgin J, Rosenberg A, Demeke DS, Rao DA, Arazi A, Celia AI, Putterman C, Anolik JH, Barnas J, Dall'Era M, Wofsy D, Furie R, Kamen D, Kalunian K, James JA, Guthridge J, Atta MG, Monroy Trujillo J, Fine D, Clancy R, Belmont HM, Izmirly P, Apruzzese W, Goldman D, Berthier CC, Hoover P, Hacohen N, Raychaudhuri S, Davidson A, Diamond B, Accelerating Medicines Partnership in RA/SLE network, Petri M. Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI insight 2024. PMID: 38258904


  36. Sandoval-Heglund D, Roberts E, Park J, Dall'Era M, Lanata C, Barbour KE, Greenlund KJ, Gordon C, Katz PP, Yazdany J. Economic insecurities and patient-reported outcomes in patients with systemic lupus erythematosus in the USA: a cross-sectional analysis of data from the California Lupus Epidemiology Study. The Lancet. Rheumatology 2023. PMID: 38267097


  37. Cutts Z, Patterson S, Maliskova L, Taylor KE, Ye C, Dall'Era M, Yazdany J, Criswell L, Fragiadakis GK, Langelier C, Capra JA, Sirota M, Lanata CM. Cell-Specific Transposable Element Gene Expression Analysis Identifies Associations with Systemic Lupus Erythematosus Phenotypes. bioRxiv : the preprint server for biology 2023. PMID: 38076936


  38. Rector I, Owen KA, Bachali P, Hubbard E, Yazdany J, Dall'era M, Grammer AC, Lipsky PE. Differential regulation of the interferon response in systemic lupus erythematosus distinguishes patients of Asian ancestry. RMD open 2023. PMID: 37709528


  39. Katz P, Patterson SL, DeQuattro K, Lanata CM, Barbour KE, Greenlund KJ, Gordon C, Criswell LA, Dall'Era M, Yazdany J. The association of trauma with self-reported flares and disease activity in systemic lupus erythematosus (SLE). Rheumatology (Oxford, England) 2022. PMID: 36477308


  40. Askanase AD, Aranow C, Kim MY, Kamen DL, Arriens C, Khalili L, Tang W, Barasch J, Dall'Era M, Mackay M. Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE. Lupus science & medicine 2023. PMID: 37429672


  41. Aguirre A, DeQuattro K, Shiboski S, Katz P, Greenlund KJ, Barbour KE, Gordon C, Lanata C, Criswel L, Dall'Era M, Yazdany J. Medication cost concerns and disparities in patient-reported outcomes among a multiethnic cohort of patients with lupus. The Journal of rheumatology 2023. PMID: 37321640


  42. Ye J, Croom N, Troxell ML, Kambham N, Zuckerman JE, Andeen N, Dall'Era M, Hsu R, Walavalkar V, Laszik ZG, Urisman A. Non-Full House Membranous Lupus Nephritis Represents a Clinically Distinct Subset. Kidney360 2023. PMID: 37257088


  43. Rua J, Dall'Era M, Isenberg D. The use of combination monoclonal antibody therapies in lupus-where are we now? Rheumatology (Oxford, England) 2023. PMID: 36106990


  44. Owen KA, Bell KA, Price A, Bachali P, Ainsworth H, Marion MC, Howard TD, Langefeld CD, Shen N, Yazdany J, Dall'era M, Grammer AC, Lipsky PE. Molecular pathways identified from single nucleotide polymorphisms demonstrate mechanistic differences in systemic lupus erythematosus patients of Asian and European ancestry. Scientific Reports 2023. PMID: 37005464


  45. Patterson S, Trupin L, Hartogensis W, DeQuattro K, Lanata C, Gordon C, Barbour KE, Greenlund KJ, Dall'Era M, Yazdany J, Katz P. Perceived Stress and Prediction of Worse Disease Activity and Symptoms in a Multiracial, Multiethnic Systemic Lupus Erythematosus Cohort. Arthritis care & research 2022. PMID: 36537191


  46. Wallace DJ, Dörner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, Le Bolay C, Drouin EE, Kao AH, Guehring H, Dall'Era M. Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial. ACR Open Rheumatology 2022. PMID: 36530019


  47. Carlucci PM, Li J, Fava A, Deonaraine KK, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, DeJager W, Guthridge JM, Haag K, Rao DA, Brenner MB, Lederer JA, Apruzzese W, Belmont HM, Izmirly PM, Zaminski D, Wu M, Connery S, Payan-Schober F, Furie R, Dall'Era M, Cho K, Kamen D, Kalunian K, Anolik J, Barnas J, Ishimori M, Weisman MH, Accelerating Medicines Partnership (AMP) RA/SLE Network, Buyon JP, Petri M. High incidence of proliferative and membranous nephritis in SLE patients with low proteinuria in the Accelerating Medicines Partnership. 2022. PMID: 35212719


  48. Dall'Era M, Kalunian K, Eaddy M, Ogbonnaya A, Farrelly E, Turowski E, Birardi V, Solomons N, Randhawa S, Mina-Osorio P. Real-world treatment utilization and economic implications of lupus nephritis disease activity in the United States. Journal of managed care & specialty pharmacy 2022. PMID: 36190835


  49. Taylor T, Anastasiou C, Ja C, Rush S, Trupin L, Dall'Era M, Katz P, Barbour KE, Greenlund KJ, Yazdany J, Gianfrancesco MA. Causes of death among individuals with systemic lupus erythematosus by race and ethnicity: a population-based study. Arthritis care & research 2022. PMID: 35904969


  50. Lanata CM, Nititham J, Taylor KE, Solomon O, Chung SA, Blazer A, Trupin L, Katz P, Dall'Era M, Yazdany J, Sirota M, Barcellos LF, Criswell LA. The dynamics of methylation of CpG sites associated with SLE subtypes in a longitudinal cohort. 2022. PMID: 35635730


  51. Kirou KA, Dall Era M, Aranow C, Anders HJ. Belimumab or anifrolumab for systemic lupus erythematosus? A risk-benefit assessment. Frontiers in immunology 2022. PMID: 36119023


  52. Aguirre A, Izadi Z, Trupin L, Barbour KE, Greenlund KJ, Katz P, Lanata C, Criswell L, Dall'Era M, Yazdany J. Race, ethnicity, and disparities in risk of end-organ lupus manifestations following SLE diagnosis in a multiethnic cohort. 2022. PMID: 35452566


  53. Urowitz MB, Aranow C, Asukai Y, Bass DL, Bruce IN, Chauhan D, Dall'Era M, Furie R, Fox NL, Gilbride JA, Hammer A, Ginzler EM, Gonzalez-Rivera T, Levy RA, Merrill JT, Quasny H, Roth DA, Stohl W, van Vollenhoven R, Wallace DJ, Petri M. Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus. Arthritis care & research 2022. PMID: 35439360


  54. Tang W, Inzerillo S, Weiner J, Khalili L, Barasch J, Gartshteyn Y, Dall'Era M, Aranow C, Mackay M, Askanase A. The Impact of Telemedicine on Rheumatology Care. Frontiers in medicine 2022. PMID: 35669922


  55. Patterson SL, Trupin L, Yazdany J, Dall'Era M, Lanata C, Dequattro K, Hartogensis W, Katz P. Physical Inactivity Independently Predicts Incident Depression in a Multi-Racial/Ethnic Systemic Lupus Cohort. Arthritis care & research 2021. PMID: 33421358


  56. DeQuattro K, Trupin L, Murphy LB, Rush S, Criswell LA, Lanata CM, Dall'Era M, Katz P, Yazdany J. High Disease Severity Among Asians in a US Multiethnic Cohort of Individuals with Systemic Lupus Erythematosus. Arthritis care & research 2020. PMID: 33337580


  57. Perez RK, Gordon MG, Subramaniam M, Kim MC, Hartoularos GC, Targ S, Sun Y, Ogorodnikov A, Bueno R, Lu A, Thompson M, Rappoport N, Dahl A, Lanata CM, Matloubian M, Maliskova L, Kwek SS, Li T, Slyper M, Waldman J, Dionne D, Rozenblatt-Rosen O, Fong L, Dall'Era M, Balliu B, Regev A, Yazdany J, Criswell LA, Zaitlen N, Ye CJ. Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus. 2022. PMID: 35389781


  58. Aringer M, Alarcón-Riquelme ME, Clowse M, Pons-Estel GJ, Vital EM, Dall'Era M. A glimpse into the future of systemic lupus erythematosus. Therapeutic advances in musculoskeletal disease 2022. PMID: 35368371


  59. van Vollenhoven R, Askanase AD, Bomback AS, Bruce IN, Carroll A, Dall'Era M, Daniels M, Levy RA, Schwarting A, Quasny HA, Urowitz MB, Zhao MH, Furie R. Conceptual framework for defining disease modification in systemic lupus erythematosus: a call for formal criteria. Lupus science & medicine 2022. PMID: 35346982


  60. Morand EF, Furie RA, Bruce IN, Vital EM, Dall'Era M, Maho E, Pineda L, Tummala R. Efficacy of anifrolumab across organ domains in patients with moderate-to-severe systemic lupus erythematosus: a post-hoc analysis of pooled data from the TULIP-1 and TULIP-2 trials. The Lancet. Rheumatology 2022. PMID: 38288923


  61. Williams JN, Dall'Era M, Lim SS, Feldman CH, Arntsen KA, Blazer AD, Goode T, Merrill JT, Sheikh S, Stevens AM, Lipsky PE, Costenbader KH. Increasing Ancestral Diversity in Systemic Lupus Erythematosus Clinical Studies. Arthritis care & research 2022. PMID: 33026693


  62. Izmirly PM, Ferucci ED, Somers EC, Wang L, Lim SS, Drenkard C, Dall'Era M, McCune WJ, Gordon C, Helmick C, Parton H. Incidence rates of systemic lupus erythematosus in the USA: estimates from a meta-analysis of the Centers for Disease Control and Prevention national lupus registries. Lupus science & medicine 2021. PMID: 34921094


  63. Deonaraine KK, Carlucci PM, Fava A, Li J, Wofsy D, James JA, Putterman C, Diamond B, Davidson A, Fine DM, Monroy-Trujillo J, Atta MG, Haag K, Rao DA, Apruzzese W, Belmont HM, Izmirly PM, Wu M, Connery S, Payan-Schober F, Furie RA, Berthier CC, Dall'Era M, Cho K, Kamen DL, Kalunian K, Anolik J, Ishimori M, Weisman MH, Accelerating Medicines Partnership RA/SLE network , Petri MA, Buyon JP. Safety of procuring research tissue during a clinically indicated kidney biopsy from patients with lupus: data from the Accelerating Medicines Partnership RA/SLE Network. 2021. PMID: 34389634


  64. Izmirly PM, Parton H, Wang L, McCune WJ, Lim SS, Drenkard C, Ferucci ED, Dall'Era M, Gordon C, Helmick CG, Somers EC. Prevalence of Systemic Lupus Erythematosus in the United States: Estimates From a Meta-Analysis of the Centers for Disease Control and Prevention National Lupus Registries. Arthritis & rheumatology (Hoboken, N.J.) 2021. PMID: 33474834


  65. Andreoletti G, Lanata CM, Trupin L, Paranjpe I, Jain TS, Nititham J, Taylor KE, Combes AJ, Maliskova L, Ye CJ, Katz P, Dall'Era M, Yazdany J, Criswell LA, Sirota M. Transcriptomic analysis of immune cells in a multi-ethnic cohort of systemic lupus erythematosus patients identifies ethnicity- and disease-specific expression signatures. Communications biology 2021. PMID: 33883687


  66. Gianfrancesco MA, Dall'Era M, Murphy LB, Helmick CG, Li J, Rush S, Trupin L, Yazdany J. Mortality Among Minority Populations with Systemic Lupus Erythematosus, Including Asian and Hispanic/Latino Persons - California, 2007-2017. MMWR. Morbidity and mortality weekly report 2021. PMID: 33600382


  67. Katz P, Dall'Era M, Trupin L, Rush S, Murphy LB, Lanata C, Criswell LA, Yazdany J. The impact of limited health literacy on patient-reported outcomes in systemic lupus erythematosus. Arthritis care & research 2020. PMID: 32741118


  68. Dietz B, Katz P, Dall'Era M, Murphy LB, Lanata C, Trupin L, Criswell LA, Yazdany J. Major Depression and Adverse Patient-Reported Outcomes in Systemic Lupus Erythematosus: Results from the California Lupus Epidemiology Study. Arthritis care & research 2020. PMID: 32741124


  69. Atisha-Fregoso Y, Malkiel S, Harris KM, Byron M, Ding L, Kanaparthi S, Barry WT, Gao W, Ryker K, Tosta P, Askanase AD, Boackle SA, Chatham WW, Kamen DL, Karp DR, Kirou KA, Lim SS, Marder B, McMahon M, Parikh SV, Pendergraft WF, Podoll AS, Saxena A, Wofsy D, Diamond B, Smilek DE, Aranow C, Dall'Era M. CALIBRATE: A Phase 2 Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis. Arthritis & rheumatology (Hoboken, N.J.) 2020. PMID: 32755035


  70. Aranow C, Cush J, Bolster MB, Striebich CC, Dall'era M, Mackay M, Olech E, Frech T, Box J, Keating R, Wasko MC, St Clair W, Kivitz A, Huang W, Ricketts P, Welch B, Callahan S, Spychala M, Boyle K, York K, Keyes-Elstein L, Goldmuntz E, Diamond B, Davidson A. A double-blind, placebo-controlled, phase II, randomized study of lovastatin therapy in the treatment of mildly active rheumatoid arthritis. Rheumatology (Oxford, England) 2020. PMID: 31628482


  71. Almaani S, Bhatt U, Arriens C, Bonfa E, Dall'Era M, Houssiau F, Kalunian K, Mackay M, Sanchez-Guerrero J, Solomons N, Rovin BH. Creatinine Fluctuation in Patients With Lupus Nephritis: Considerations for Clinical Trial Endpoints. Kidney international reports 2020. PMID: 32775830


  72. Aggarwal I, Li J, Trupin L, Gaynon L, Katz PP, Lanata C, Criswell L, Murphy LB, Dall'Era M, Yazdany J. Quality of Care for the Screening, Diagnosis, and Management of Lupus Nephritis Across Multiple Healthcare Settings. Arthritis care & research 2019. PMID: 31058460


  73. Maningding E, Dall'Era M, Trupin L, Murphy LB, Yazdany J. Racial/Ethnic Differences in Prevalence of and Time to Onset of SLE Manifestations: The California Lupus Surveillance Project (CLSP). Arthritis care & research 2019. PMID: 31115180


  74. DeQuattro K, Trupin L, Li J, Katz PP, Murphy LB, Yelin EH, Rush S, Lanata C, Criswell LA, Dall'Era M, Yazdany J. Relationships Between Adverse Childhood Experiences and Health Status in Systemic Lupus Erythematosus. Arthritis care & research 2019. PMID: 31069933


  75. Lanata CM, Paranjpe I, Nititham J, Taylor KE, Gianfrancesco M, Paranjpe M, Andrews S, Chung SA, Rhead B, Barcellos LF, Trupin L, Katz P, Dall'Era M, Yazdany J, Sirota M, Criswell LA. Author Correction: A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. Nature communications 2020. PMID: 32109229


  76. Floren LC, Mandal J, Dall'Era M, Shin J, Irby DM, Cate OT, O'Brien BC. A Mobile Learning Module to Support Interprofessional Knowledge Construction in the Health Professions. American journal of pharmaceutical education 2020. PMID: 32226076


  77. Katz P, Pedro S, Alemao E, Yazdany J, Dall'Era M, Trupin L, Rush S, Michaud K. Estimates of Responsiveness, Minimally Important Differences, and Patient Acceptable Symptom State in Five Patient-Reported Outcomes Measurement Information System Short Forms in Systemic Lupus Erythematosus. ACR Open Rheumatology 2019. PMID: 31943975


  78. Katz P, Yazdany J, Trupin L, Rush S, Helmick CG, Murphy LB, Lanata C, Criswell LA, Dall'Era M. Psychometric evaluation of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS® ) in a multi-racial, multi-ethnic systemic lupus erythematosus (SLE) cohort. Arthritis care & research 2018. PMID: 30354017


  79. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B. Publisher Correction: The immune cell landscape in kidneys of patients with lupus nephritis. Nature immunology 2019. PMID: 31409923


  80. Lanata CM, Paranjpe I, Nititham J, Taylor KE, Gianfrancesco M, Paranjpe M, Andrews S, Chung SA, Rhead B, Barcellos LF, Trupin L, Katz P, Dall'Era M, Yazdany J, Sirota M, Criswell LA. A phenotypic and genomics approach in a multi-ethnic cohort to subtype systemic lupus erythematosus. Nature communications 2019. PMID: 31467281


  81. Arazi A, Rao DA, Berthier CC, Davidson A, Liu Y, Hoover PJ, Chicoine A, Eisenhaure TM, Jonsson AH, Li S, Lieb DJ, Zhang F, Slowikowski K, Browne EP, Noma A, Sutherby D, Steelman S, Smilek DE, Tosta P, Apruzzese W, Massarotti E, Dall'Era M, Park M, Kamen DL, Furie RA, Payan-Schober F, Pendergraft WF, McInnis EA, Buyon JP, Petri MA, Putterman C, Kalunian KC, Woodle ES, Lederer JA, Hildeman DA, Nusbaum C, Raychaudhuri S, Kretzler M, Anolik JH, Brenner MB, Wofsy D, Hacohen N, Diamond B. The immune cell landscape in kidneys of patients with lupus nephritis. Nature immunology 2019. PMID: 31209404


  82. Singh JA, Fraenkel L, Green C, Alarcón GS, Barton JL, Saag KG, Hanrahan LM, Raymond SC, Kimberly RP, Leong AL, Reyes E, Street RL, Suarez-Almazor ME, Eakin GS, Marrow L, Morgan CJ, Caro B, Sloan JA, Jandali B, Garcia SR, Grossman J, Winthrop KL, Trupin L, Dall'Era M, Meara A, Rizvi T, Chatham WW, Yazdany J. Individualized decision aid for diverse women with lupus nephritis (IDEA-WON): A randomized controlled trial. PLoS medicine 2019. PMID: 31067237


  83. Gomez Mendez LM, Cascino MD, Katsumoto TR, Brakeman P, Brunetta P, Jayne D, Dall'Era M, Rovin B, Garg J. Outcome of participants with nephrotic syndrome in combined clinical trials of lupus nephritis. Lupus science & medicine 2019. PMID: 31080631


  84. Mackay M, Dall'Era M, Fishbein J, Kalunian K, Lesser M, Sanchez-Guerrero J, Levy DM, Silverman E, Petri M, Arriens C, Lewis EJ, Korbet SM, Conti F, Tesar V, Hruskova Z, Borba EF, Bonfa E, Chan TM, Rathi M, Gupta KL, Jha V, Hasni S, West MR, Solomons N, Houssiau FA, Romero-Diaz J, Mejia-Vilet J, Rovin BH. Establishing Surrogate Kidney End Points for Lupus Nephritis Clinical Trials: Development and Validation of a Novel Approach to Predict Future Kidney Outcomes. Arthritis & rheumatology (Hoboken, N.J.) 2019. PMID: 30225865


  85. Dall'Era M, Pauli ML, Remedios K, Taravati K, Sandoval PM, Putnam AL, Lares A, Haemel A, Tang Q, Hellerstein M, Fitch M, McNamara J, Welch B, Bluestone JA, Wofsy D, Rosenblum MD. Adoptive Regulatory T Cell Therapy in a Patient with Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) 2018. PMID: 30277008


  86. Dall'Era M, Bruce IN, Gordon C, Manzi S, McCaffrey J, Lipsky PE. Current challenges in the development of new treatments for lupus. Annals of the rheumatic diseases 2019. PMID: 30636212


  87. Sciascia S, Yazdany J, Dall'Era M, Fenoglio R, Radin M, Aggarwal I, Cuadrado MJ, Schreiber K, Barreca A, Papotti M, Roccatello D. Anticoagulation in patients with concomitant lupus nephritis and thrombotic microangiopathy: a multicentre cohort study. Annals of the rheumatic diseases 2018. PMID: 30552172


  88. Gomez Mendez LM, Cascino MD, Garg J, Katsumoto TR, Brakeman P, Dall'Era M, Looney RJ, Rovin B, Dragone L, Brunetta P. Peripheral Blood B Cell Depletion after Rituximab and Complete Response in Lupus Nephritis. Clinical journal of the American Society of Nephrology : CJASN 2018. PMID: 30089664


  89. Merrill JT, Manzi S, Aranow C, Askanase A, Bruce I, Chakravarty E, Chong B, Costenbader K, Dall'Era M, Ginzler E, Hanrahan L, Kalunian K, Merola J, Raymond S, Rovin B, Saxena A, Werth VP. Lupus community panel proposals for optimising clinical trials: 2018. Lupus science & medicine 2018. PMID: 29657738


  90. Dall'Era M, Cisternas MG, Snipes K, Herrinton LJ, Gordon C, Helmick CG. The Incidence and Prevalence of Systemic Lupus Erythematosus in San Francisco County, California: The California Lupus Surveillance Project. Arthritis & rheumatology (Hoboken, N.J.) 2017. PMID: 28891237


  91. Dall'Era M. Treatment of lupus nephritis: current paradigms and emerging strategies. Current opinion in rheumatology 2017. PMID: 28207493


  92. Sciascia S, Radin M, Yazdany J, Tektonidou M, Cecchi I, Roccatello D, Dall'Era M. Expanding the therapeutic options for renal involvement in lupus: eculizumab, available evidence. Volume 37 of Issue 8. Rheumatology international 2017. PMID: 28258475


  93. Qu H, Shewchuk RM, Alarcón G, Fraenkel L, Leong A, Dall'Era M, Yazdany J, Singh JA. Mapping Perceptions of Lupus Medication Decision-Making Facilitators: The Importance of Patient Context. Volume 68 of Issue 12. Arthritis care & research 2016. PMID: 27059939


  94. Doedens JR, Jones WD, Hill K, Mason MJ, Gersuk VH, Mease PJ, Dall'Era M, Aranow C, Martin RW, Cohen SB, Fleischmann RM, Kivitz AJ, Burge DJ, Chaussabel D, Elkon KB, Posada JA. Blood-Borne RNA Correlates with Disease Activity and IFN-Stimulated Gene Expression in Systemic Lupus Erythematosus. Journal of immunology (Baltimore, Md. : 1950) 2016. PMID: 27534558


  95. Tamirou F, Lauwerys BR, Dall'Era M, Mackay M, Rovin B, Cervera R, Houssiau FA, MAINTAIN Nephritis Trial Investigators. A proteinuria cut-off level of 0.7 g/day after 12 months of treatment best predicts long-term renal outcome in lupus nephritis: data from the MAINTAIN Nephritis Trial. Lupus science & medicine 2015. PMID: 26629352


  96. Singh JA, Qu H, Yazdany J, Chatham W, Dall'era M, Shewchuk RM. Barriers to Medication Decision Making in Women with Lupus Nephritis: A Formative Study using Nominal Group Technique. Volume 42 of Issue 9. The Journal of rheumatology 2015. PMID: 26178276


  97. Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, Diamond B. Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus. Arthritis & rheumatology (Hoboken, N.J.) 2015. PMID: 25777546


  98. Dall'Era M, Levesque V, Solomons N, Truman M, Wofsy D. Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Volume 2 of Issue 1. Lupus science & medicine 2015. PMID: 26023331


  99. Dall'Era M, Cisternas MG, Smilek DE, Straub L, Houssiau FA, Cervera R, Rovin BH, Mackay M. Predictors of long-term renal outcome in lupus nephritis trials: lessons learned from the Euro-Lupus Nephritis cohort. Volume 67 of Issue 5. Arthritis & rheumatology (Hoboken, N.J.) 2015. PMID: 25605554


  100. Ashouri JF, Davis JL, Farkas A, Durack JC, Ramachandran R, Dall'Era M. A young woman with systemic lupus erythematosus and extensive mesenteric vasculitis involving small and medium vessels. Arthritis care & research 2012. PMID: 22933330


  101. Dall'Era M. Mycophenolate mofetil in the treatment of systemic lupus erythematosus. Current opinion in rheumatology 2011. PMID: 21720247


  102. Yazdany J, Trupin L, Gansky SA, Dall'era M, Yelin EH, Criswell LA, Katz PP. Brief index of lupus damage: a patient-reported measure of damage in systemic lupus erythematosus. Volume 63 of Issue 8. Arthritis care & research 2011. PMID: 21584946


  103. Dall'era M, Chakravarty EF. Treatment of mild, moderate, and severe lupus erythematosus: focus on new therapies. Current rheumatology reports 2011. PMID: 21584692


  104. Dall'Era M, Stone D, Levesque V, Cisternas M, Wofsy D. Identification of biomarkers that predict response to treatment of lupus nephritis with mycophenolate mofetil or pulse cyclophosphamide. Volume 63 of Issue 3. Arthritis care & research 2010. PMID: 21080348


  105. Dillon SR, Harder B, Lewis KB, Moore MD, Liu H, Bukowski TR, Hamacher NB, Lantry MM, Maurer M, Krejsa CM, Ellsworth JL, Pederson S, Elkon KB, Wener MH, Dall'Era M, Gross JA. B-lymphocyte stimulator/a proliferation-inducing ligand heterotrimers are elevated in the sera of patients with autoimmune disease and are neutralized by atacicept and B-cell maturation antigen-immunoglobulin. Arthritis research & therapy 2010. PMID: 20302641


  106. Dall'Era M, Wofsy D. Connective tissue diseases: Belimumab for systemic lupus erythematosus: breaking through? Volume 6 of Issue 3. Nature reviews. Rheumatology 2010. PMID: 20197774


  107. Dall'Era M, Wofsy D. Biologic therapy for systemic lupus erythematosus. Volume 9 of Issue 44. Discovery medicine 2010. PMID: 20102681


  108. Dall'Era M, Wofsy D. Systemic lupus erythematosus clinical trials-an interim analysis. Volume 5 of Issue 6. Nature reviews. Rheumatology 2009. PMID: 19491915


  109. Dall'Era M, Chakravarty E, Wallace D, Genovese M, Weisman M, Kavanaugh A, Kalunian K, Dhar P, Vincent E, Pena-Rossi C, Wofsy D. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Volume 56 of Issue 12. Arthritis and rheumatism 2007. PMID: 18050206


  110. Gillis JZ, Dall'era M, Gross A, Yazdany J, Davis J. Six refractory lupus patients treated with rituximab: a case series. Volume 57 of Issue 3. Arthritis and rheumatism 2007. PMID: 17394185


  111. Dall'Era M, Wofsy D. Clinical trial design in systemic lupus erythematosus. Volume 18 of Issue 5. Current opinion in rheumatology 2006. PMID: 16896285


  112. Dall'Era M, Davis JC. Systemic lupus erythematosus. How to manage, when to refer. Postgraduate medicine 2003. PMID: 14650091